PDSB News and Press, PDS Biotechnology Corporation From 09/13/21

Raising Our Price Target PDS Biotech announced that it has completed enrollment of the safety cohort in the Phase 2 VERSATILE-002 study. This is one of the clinical milestones we had expected in 2H21. We believe this shows development progress as well as proof-of-concept for the Versamune tech...

FLORHAM PARK, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, today announced that it ...

FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, announced today that its...

PDS Biotechnology Corporation (NASDAQ:PDSB) traded at a new 52-week high today of $14.11. So far today approximately 4 million shares have been exchanged, as compared to an average 30-day volume of 473,000 shares. PDS Biotechnology Corp operates as a clinical stage biotechnology company,...

Significant Data Was Presented In 2Q21. PDS Biotechnology reported 2Q21 loss of $0.6 million or $(0.03) per share. Importantly, interim Phase 2 data from the lead trial for PDS0101 presented at the ASCO conference showed strong indications of efficacy. Additional data from this PDS0101 trial a...

PDS Biotechnology Corporation (PDSB) Q2 2021 Earnings Conference Call August 12, 2021 08:00 AM ET Company Participants Deanne Randolph - VP, Commercial Development & Head, IR Frank Bedu-Addo - President, CEO & Director Lauren Wood - Chief Medical Officer Seth Van Voorhees - CFO, Princ...

The following slide deck was published by PDS Biotechnology Corporation in conjunction with their 2021 Q2 earnings call. For further details see: PDS Biotechnology Corporation 2021 Q2 - Results - Earnings Call Presentation

FLORHAM PARK, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, will discuss its financia...

FLORHAM PARK, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, announced today that its ...

FLORHAM PARK, N.J., July 26, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, will release financial re...